Shilpa Medicare Ltd

🚨 Delhi High Court Issues Injunction Against Shilpa Medicare Over Ruxolitinib Patent

- Delhi High Court issued an ex parte ad-interim injunction against Shilpa Medicare Ltd. and subsidiaries.

- Restricts manufacturing, stockpiling, exporting, or selling Ruxolitinib-based products due to patent infringement (Patent No. IN269841).

- Local Commissioner inspected premises; company fully cooperated.

- Product in question was used only for research—no financial impact.

- Business operations remain unaffected.

- Legal response under evaluation, including potential appeals.